Heterogeneity of Adult Rhinitis for Multimorbidity and Age at Onset among Non-Sensitized Rhinitis and Mono-/Poly-Sensitized Rhinitis: A Retrospective Cross-Sectional Study

Jeong, Jae Won; Lim, Ki Moo; Lee, Woo Hyun; Won, Jun Yeon; Kwon, Jae-Woo

doi:10.1159/000507444

Cited by 4 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increased risk of AR in patients with AD has been seen in multiple studies using different research strategies (i.e., prospective, population‐based, cross‐sectional) in different age groups and in different continents (Asia, Europe). This supports the notion that AR and AD are related diseases 739,2854,3055–3064 …”

Section: Associated Conditionssupporting

confidence: 87%

“…In one study, for example, less than half of all patients reporting AR had a physician‐confirmed diagnosis of AR 3054 . Therefore, the link between AR and AD remains poorly defined due to methodologic differences and limitations of the studies that have examined this association 739,2854,3055–3065 (Table XIII.D).…”

Section: Associated Conditionsmentioning

confidence: 99%

“…Multiple studies performed in different countries and age groups, using a variety of methodologies, conclude that there is a disease association between AR and AD. The available evidence suggests that there is a two‐ to four‐fold increase in AR among people with AD 739,2854,3055–3064,3071 . For example, in the cross‐sectional multicenter study titled “Epidemiology of Allergic Diseases in Poland” conducted in children age 6–7 and 13–14 years and adults aged 20–44 years, allergic diseases were common in children and young adults.…”

Section: Associated Conditionsmentioning

confidence: 99%

See 2 more Smart Citations

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Wise

Damask

Roland

et al. 2023

Int Forum Allergy Rhinol

113

View full text Add to dashboard Cite

Background In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR‐Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence‐based findings and recommendation from the full document. Methods ICAR‐Allergic Rhinitis 2023 employed established evidence‐based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work. Results ICAR‐Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost. Conclusion The ICAR‐Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.

show abstract

Section: Associated Conditionssupporting

confidence: 87%

Section: Associated Conditionsmentioning

confidence: 99%

Section: Associated Conditionsmentioning

confidence: 99%

See 1 more Smart Citation